Physician

Ari D Baron, M.D.

According to 2025 Medicare claims, Ari Baron, M.D. (NPI: 1013086420) practices hematology/oncology in the San Francisco-San Mateo-Redwood City, CA market, with the plurality of this provider's patient population coming from San Francisco, CA. This provider's primary affiliated billing organization is PACIFIC HEMATOLOGY ONCOLOGY ASSOC (NPI: 1073630406; TIN: 942547219) and primary practice location at 94115-2376.

Baron's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 584 traditional Medicare patients, billed 143,015 HCPCS/CPT codes, and received $2,447,280 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 2,751 prescription claims across 274 beneficiaries totaling $16,390,699 in drug costs, led by Nubeqa (Darolutamide). DME data shows 27 claims. Open Payments data shows 125 records totaling $157,555. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $3,986,422 to $16,390,699. In contrast, DME billing represents a smaller volume and fell sharply in recent years, from $11,335 to $2,157.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	467	171,328	$2,091,376
2016	538	193,747	$2,206,008
2017	521	243,051	$2,300,616
2018	500	245,014	$2,364,421
2019	525	152,278	$1,972,705
2020	509	130,939	$2,384,567
2021	510	133,850	$2,374,979
2022	577	139,403	$2,532,120
2023	558	132,238	$2,410,783
2024	584	143,015	$2,447,280

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	226	1,766	$3,986,422
2016	229	2,082	$4,401,027
2017	249	2,577	$5,958,049
2018	263	2,629	$8,042,474
2019	281	3,315	$11,822,332
2020	290	3,852	$13,105,074
2021	292	4,450	$17,520,499
2022	314	4,023	$19,676,944
2023	307	3,432	$19,686,991
2024	274	2,751	$16,390,699

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	48	325	$40,296
2016	44	538	$115,217
2017	56	893	$149,215
2018	75	573	$33,049
2019	86	368	$20,634
2020	22	207	$10,767
2021	N/R	113	$6,656
2022	30	109	$3,299
2023	N/R	N/R	N/R
2024	N/R	27	$612

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	164	297	$161
96413	Administration of chemotherapy into vein, 1 hour or less	85	456	$136
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	434	917	$111
96372	Injection of drug or substance under skin or into muscle	109	454	$13
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	200	975	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Nubeqa	Darolutamide	398	11,970	$5,280,039
Lupron Depot	Leuprolide Acetate	133	11,472	$809,746
Keytruda	Pembrolizumab	69	1,449	$773,826
Revlimid	Lenalidomide	34	924	$647,896
Lynparza	Olaparib	38	1,140	$622,037

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	12	$330
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	15	$282

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	116	$49,173	E.R. Squibb & Sons, L.L.C.
Research Payments	Reported research-related payment or transfer-of-value amount.	9	$108,383	AstraZeneca UK Limited
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Ari D. Baron, M.D.?

Tedicare shows public-source Medicare data for Ari D. Baron, M.D. (NPI 1013086420), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Ari D. Baron, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Ari D. Baron, M.D.?

Ari D. Baron, M.D. is linked to PACIFIC HEMATOLOGY ONCOLOGY ASSOC (billing NPI 1073630406) in the available physician profile data.

Does Ari D. Baron, M.D. have Open Payments data?

Ari D. Baron, M.D. has 125 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.